Contributions
Abstract: EP1478
Type: ePoster
Abstract Category: Therapy - disease modifying - Immunomodulation/Immunosuppression
Background: Comorbidities are common in multiple sclerosis (MS) and adversely affect health outcomes. However, how comorbidities may influence physician"s choice of different disease-modifying treatments (DMTs) in MS remains unknown.
Objective: To determine the prevalence of comorbidities in a large cohort of MS patients residents in the Lazio region at the time of MS diagnosis. To examine the effects of comorbidity on the choice of the initial DMT in MS.
Methods: A large (n = 1713) sample of adults with MS was recruited from 5 MS clinics. Comorbidities and prescriptions of different DMTs were assessed linking clinical and administrative (health information systems) data. We selected patients with the first pharmacy claim in the study period (from January 2008 to December 2010) for at least one DMT among IFNbeta-1a i.m. (n=405), IFNbeta-1a s.c. (n=524), IFNbeta-1b (n=439), and Glatiramer Acetate (GA) (n=345).
Results: Of the MS cases, 67.1% were females. At least one comorbidity occurred in 22.6% of the population. Depression, autoimmune diseases and hypertension were the most common comorbidities. At the time of the first DMT prescription, the mean age was 38.0 for IFNbeta-1a i.m.; 36.1 for IFNbeta-1a s.c.; 39.9 for IFNbeta 1b; 44.7 for GA (p< 0.001); 20.5% of the population was above 45 years in the IFNbeta-1a i.m group ; 17.3% in the IFNbeta-1a s.c group.; 30% in the IFNbeta 1b group and 49.6% in the GA group. The presence of >1comorbidities was 4.4% for IFNbeta-1a i.m.; 4.8% for IFNbeta-1a s.c.; 5.2% for IFNbeta 1b; 10.1 for GA (p< 0.001).
Conclusions: Age and comorbidities of the patients influence decisions regarding DMTs in MS. Ga is preferred to IFNbeta treatments in older people and in those with more than one comorbidity.
Disclosure: The present study was funded by the Lazio region Pharmacovigilance call 2011
C Pozzilli has received consulting and lecture fees from Bayer Schering, Biogen, Merck-Serono, Novartis, and Sanofi-Aventis; has received research funding from Bayer Schering, Merck Serono, Novartis, and Sanofi-Aventis.
C Gasperini received fee as speaker for Bayer-Schering Pharma, Sanofi-Aventis, Genzyme, Biogen, Teva, Novartis, Merck Serono. Received a grant for research by Teva.
AM Bargagli: nothing to disclose
S Cascini: nothing to disclose
F Buttari acted as Advisory Board member of Teva and received funding for traveling from Novartis, Teva, Merck Serono, Almirall, Biogen.
D Centonze is an Advisory Board member of Almirall, Bayer Schering, Biogen, Genzyme, GW Pharmaceuticals, Merck-Serono, Novartis, Teva and received honoraria for speaking or consultation fees from Almirall, Bayer Schering, Biogen Idec, Genzyme, GW Pharmaceuticals, Merck Serono, Novartis, Sanofi, Teva. He is also the principal investigator in clinical trials for Bayer Schering, Biogen Idec, Merck Serono, Mitsubishi, Novartis, Roche, Sanofi, Teva. His preclinical and clinical research was supported by grants from Bayer, Biogen, Merck Serono, Novartis e Teva.
M Di Folco: nothing to disclose
A Francia: nothing to disclose
S Galgani: Dr Galgani has received honoraria for scientific advisory board from Biogen Merck Serono Genzyme.Dr Galgani has received funding for travel and speaker honoraria from Biogen,Teva,Merck Serono,Novartis ,Sanofi Aventis , Genzyme,Shering,Almiral Almiral
M Giuliani: nothing to disclose
P Colais: nothing to disclose
M Mirabella has received honoraria for scientific lectures and advisory board activities from Biogen Novartis, Teva, Sanofi Genzyme, Bayer Shering, Merck Serono, Almirall and research support from Merck Serono, Novartis, Teva, Genzyme.
V Nociti has received honoraria for scientific advisory boards for Novartis, Teva, Biogen Idec, Sanofi-Aventis Genzyme, and Bayer Schering, has received funding for travel and speaker honoraria from Teva, Biogen Idec, Bayer Schering, Merck Serono, Almirall, Genzyme and Novartis, and receives research support from Almirall.
M Davoli: nothing to disclose
Abstract: EP1478
Type: ePoster
Abstract Category: Therapy - disease modifying - Immunomodulation/Immunosuppression
Background: Comorbidities are common in multiple sclerosis (MS) and adversely affect health outcomes. However, how comorbidities may influence physician"s choice of different disease-modifying treatments (DMTs) in MS remains unknown.
Objective: To determine the prevalence of comorbidities in a large cohort of MS patients residents in the Lazio region at the time of MS diagnosis. To examine the effects of comorbidity on the choice of the initial DMT in MS.
Methods: A large (n = 1713) sample of adults with MS was recruited from 5 MS clinics. Comorbidities and prescriptions of different DMTs were assessed linking clinical and administrative (health information systems) data. We selected patients with the first pharmacy claim in the study period (from January 2008 to December 2010) for at least one DMT among IFNbeta-1a i.m. (n=405), IFNbeta-1a s.c. (n=524), IFNbeta-1b (n=439), and Glatiramer Acetate (GA) (n=345).
Results: Of the MS cases, 67.1% were females. At least one comorbidity occurred in 22.6% of the population. Depression, autoimmune diseases and hypertension were the most common comorbidities. At the time of the first DMT prescription, the mean age was 38.0 for IFNbeta-1a i.m.; 36.1 for IFNbeta-1a s.c.; 39.9 for IFNbeta 1b; 44.7 for GA (p< 0.001); 20.5% of the population was above 45 years in the IFNbeta-1a i.m group ; 17.3% in the IFNbeta-1a s.c group.; 30% in the IFNbeta 1b group and 49.6% in the GA group. The presence of >1comorbidities was 4.4% for IFNbeta-1a i.m.; 4.8% for IFNbeta-1a s.c.; 5.2% for IFNbeta 1b; 10.1 for GA (p< 0.001).
Conclusions: Age and comorbidities of the patients influence decisions regarding DMTs in MS. Ga is preferred to IFNbeta treatments in older people and in those with more than one comorbidity.
Disclosure: The present study was funded by the Lazio region Pharmacovigilance call 2011
C Pozzilli has received consulting and lecture fees from Bayer Schering, Biogen, Merck-Serono, Novartis, and Sanofi-Aventis; has received research funding from Bayer Schering, Merck Serono, Novartis, and Sanofi-Aventis.
C Gasperini received fee as speaker for Bayer-Schering Pharma, Sanofi-Aventis, Genzyme, Biogen, Teva, Novartis, Merck Serono. Received a grant for research by Teva.
AM Bargagli: nothing to disclose
S Cascini: nothing to disclose
F Buttari acted as Advisory Board member of Teva and received funding for traveling from Novartis, Teva, Merck Serono, Almirall, Biogen.
D Centonze is an Advisory Board member of Almirall, Bayer Schering, Biogen, Genzyme, GW Pharmaceuticals, Merck-Serono, Novartis, Teva and received honoraria for speaking or consultation fees from Almirall, Bayer Schering, Biogen Idec, Genzyme, GW Pharmaceuticals, Merck Serono, Novartis, Sanofi, Teva. He is also the principal investigator in clinical trials for Bayer Schering, Biogen Idec, Merck Serono, Mitsubishi, Novartis, Roche, Sanofi, Teva. His preclinical and clinical research was supported by grants from Bayer, Biogen, Merck Serono, Novartis e Teva.
M Di Folco: nothing to disclose
A Francia: nothing to disclose
S Galgani: Dr Galgani has received honoraria for scientific advisory board from Biogen Merck Serono Genzyme.Dr Galgani has received funding for travel and speaker honoraria from Biogen,Teva,Merck Serono,Novartis ,Sanofi Aventis , Genzyme,Shering,Almiral Almiral
M Giuliani: nothing to disclose
P Colais: nothing to disclose
M Mirabella has received honoraria for scientific lectures and advisory board activities from Biogen Novartis, Teva, Sanofi Genzyme, Bayer Shering, Merck Serono, Almirall and research support from Merck Serono, Novartis, Teva, Genzyme.
V Nociti has received honoraria for scientific advisory boards for Novartis, Teva, Biogen Idec, Sanofi-Aventis Genzyme, and Bayer Schering, has received funding for travel and speaker honoraria from Teva, Biogen Idec, Bayer Schering, Merck Serono, Almirall, Genzyme and Novartis, and receives research support from Almirall.
M Davoli: nothing to disclose